Association analyses between the variants of SNAP25, SV2C and ST3GAL2 and the efficacy of botulinum toxin A in the treatment of the primary Meige syndrome.

Objective: Individual differences were observed in the clinical efficacy of Botulinum toxin A (BoNT-A) in the treatment of the primary Meige syndrome. Our study aimed to explore the potential associations between the clinical efficacy of BoNT-A in the treatment of the primary Meige syndrome and variants of SNAP25, SV2C and ST3GAL2, which are involving in the translocation of the BoNT-A in vivo. Methods: Patients with the primary Meige syndrome treated with BoNT-A were enrolled. Clinical efficacy was evaluated by the maximum improvement rate of motor symptoms and the duration of efficacy. Variants of SNAP25, SV2C and ST3GAL2 were obtained by Sanger sequencing. Another cohort diagnosed with primary cervical dystonia was also enrolled in the replication stage. Results: Among the 104 primary Meige syndrome patients, 80 patients (76.9%) had a good efficacy (the maximum improvement rate of motor symptoms ≥30%) and 24 (23. 1%) had a poor (the maximum improvement rate of motor symptoms <30%). As to the duration of efficacy, 52 patients (50.0%) had a long duration of efficacy (≥4 months), and 52 (50.0%) had a short (<4 months). In terms of primary Meige syndrome, SNAP25 rs6104571 was found associating with the maximum improvement rate of motor symptoms (Genotype: P = 0.02, OR = 0.26; Allele: P = 0.013, OR = 0.29), and SV2C rs31244 was found associating with the duration of efficacy (Genotype: P = 0.024, OR = 0.13; Allele: P = 0.012, OR = 0.13). Besides, we also conducted the association analyses between the variants and BoNT-A-related adverse reactions. Although, there was no statistical difference between the allele of SV2C rs31244 and BoNT-A-related adverse reactions, there was a trend (P = 0.077, OR = 2.56). In the replication stage, we included 39 patients with primary cervical dystonia to further expanding the samples' size. Among the 39 primary cervical dystonia patients, 25 patients (64.1%) had a good efficacy (the maximum improvement rate of motor symptoms ≥50%) and 14 (35.9%) had a poor (the maximum improvement rate of motor symptoms <50%). As to the duration of efficacy, 32 patients (82.1%) had a long duration of efficacy (≥6 months), and 7 (17.9%) had a short (<6 months). Integrating primary Meige syndrome and primary cervical dystonia, SV2C rs31244 was still found associating with the duration of efficacy (Genotype: P = 0.002, OR = 0. 23; Allele: P = 0.001, OR = 0. 25). Conclusion: In our study, SNAP25 rs6104571 was associated with the maximum improvement rate of motor symptoms in patients with primary Meige syndrome treated with BoNT-A, and patients carrying this variant had a lower improvement rate of motor symptoms. SV2C rs31244 was associated with duration of treatment in patients with primary Meige syndrome treated with BoNT-A and patients carrying this variant had a shorter duration of treatment. Patients with primary Meige syndrome carrying SV2C rs31244 G allele have an increase likelihood of BoNT-A-related adverse reactions. Involving 39 patients with primary cervical dystonia, the results further verify that SV2C rs31244 was associated with duration of treatment and patients carrying this variant had a shorter duration of treatment.

Unique cation-template three-dimensional hybrid material demonstrates dielectric switchable response.

The strict tolerance space of three-dimensional (3D) crystalline structures is still a significant challenge in the area of switching dielectrics in comparison with lower-dimensional structures. Generally, the function of crystalline materials can be given or adjusted by controlling the environment in which synthesis takes place or the packing rearrangement. Using this method, special functional enhancements or changes in the dielectrics can be realized by improving the synthetic strategies. Here, a 3D switchable dielectric compound [MeHdabco]K(BF4)3 was achieved by employing the temperature selective effect. In particular, its structure is completely different from the usual 3D perovskite structure, which is constructed using two different cation-template frameworks. Moreover, the 3D [MeHdabco]K(BF4)3 shows a structural phase transition at 358 K. The thermal analysis (differential scanning calorimetry (DSC)) and X-ray diffractometry results provided evidence of these phase changes. This work provides a feasible strategy that can be used to achieve the different structures of an 'isomer', and enrich the method used for designing diverse functional materials.

Three-Dimensional Metal-Free Molecular Perovskite with a Thermally Induced Switchable Dielectric Response.

Temperature-responsive materials with switching physical properties have been widely researched. Among them, the switchable dielectric perovskite materials show potential applications in the electrical and electronic industries and even the intelligence industries. However, perovskite oxides and hybrid organic-inorganic perovskites, as the most representative switchable dielectric materials, are limited by bad biocompatibility. Herein, we report temperature-dielectric-responsive metal-free perovskite (H2dabco)(NH4)[BF4]3 constructed by the strategy of substituting the B site in the general formula ABX3 (doubly protonated 1,4-diazabicyclo[2.2.2]octane = H2dabco). Meanwhile, structurally similar hybrid material (H2dabco)Rb[BF4]3 was designed as a control. They exhibit similar phase-transition characteristics and dielectric response behaviors around 333 K. More interestingly, the ordered-disordered transformation of their organic "spherical" cations (H2dabco) was deemed to produce their phase transitions and dielectric response switching. Given its ability to generate a dielectric response, (H2dabco)(NH4)[BF4]3 will show the potential application of metal-free perovskite in a future thermal sensing device.